FIERCELY FOCUSED
ON SOLUTIONS

COLLABORATE WITH US

We are deeply committed to advancing our scientific and clinical understanding of B-cell diseases and the impact our investigational medicines may have on these diseases and patients. We also believe in the power of partnership and are interested in strategically expanding our pipeline and accelerating our ability to develop innovative combination treatments to enhance the treatment of patients with B-cell diseases.

For more information or to discuss the potential to collaborate with TG Therapeutics on preclinical or clinical research programs, please contact us at [email protected].

For more information or to discuss potential business development initiatives or partnering opportunities with TG, please contact us at [email protected].

TG Therapeutics logo
X-twitter Linkedin
footer-hex
Scroll to Top
Important Safety Information
CONTRAINDICATIONS: BRIUMVI is contraindicated in patients with:
  • Active HBV infection
  • A history of life-threatening infusion reaction to BRIUMVI
 		Indication
BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
CONTRAINDICATIONS: BRIUMVI is contraindicated in patients with:
  • Active HBV infection
  • A history of life-threatening infusion reaction to BRIUMVI